MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Iovance Biotherapeutics Inc

Closed

SectorHealthcare

1.75 1.16

Overview

Share price change

24h

Current

Min

1.73

Max

1.79

Key metrics

By Trading Economics

Income

-38M

-116M

Sales

-24M

49M

EPS

-0.36

Profit margin

-235.51

Employees

838

EBITDA

-35M

-110M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+474.71% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-594M

574M

Previous open

0.59

Previous close

1.75

News Sentiment

By Acuity

50%

50%

163 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jul 2025, 17:03 UTC

Major Market Movers

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 Jul 2025, 15:18 UTC

Major Market Movers

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 Jul 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jul 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 Jul 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T and TPG Close DIRECTV Transaction

2 Jul 2025, 20:26 UTC

Earnings

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 Jul 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 Jul 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 Jul 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 Jul 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 Jul 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 Jul 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 Jul 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 Jul 2025, 17:05 UTC

Acquisitions, Mergers, Takeovers

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2 Jul 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 Jul 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 Jul 2025, 15:59 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 Jul 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 Jul 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2 Jul 2025, 15:00 UTC

Acquisitions, Mergers, Takeovers

Glencore: Merger of Viterra With Bunge Global Closed

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

474.71% upside

12 Months Forecast

Average 10 USD  474.71%

High 25 USD

Low 2 USD

Based on 11 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

3.0208 / 3.5Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

163 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.